Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD

D Ezhilarasan - Metabolism, 2024 - Elsevier
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …
被引用次数：2 相关文章

Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD

D Ezhilarasan - Metabolism: clinical and experimental - pubmed.ncbi.nlm.nih.gov
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …

Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD

D Ezhilarasan - Metabolism-Clinical and Experimental, 2024 - metabolismjournal.com
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …

Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.

D Ezhilarasan - Metabolism: Clinical and Experimental, 2024 - europepmc.org
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …